Prostate Cancer Cases Rising 3 Percent Annually in the US, With Advanced Diagnoses Climbing Fastest
The American Cancer Society projects 333,830 new prostate cancer cases in the US in 2026, with incidence rising 3 percent per year since 2014. The sharpest increase is in advanced-stage diagnoses, raising concern among oncologists about delayed screening.
Prostate cancer cases in the United States have been rising at 3% per year since 2014, according to the American Cancer Society's Cancer Statistics 2026 report. The ACS projects 333,830 new diagnoses and 36,320 deaths from the disease in 2026.
The most alarming trend is the increase in advanced-stage diagnoses. Distant-stage prostate cancer has risen annually across all age groups: 2.6% in men under 55, 6.0% in men aged 55 to 69, and 6.2% in men 70 and older.
William Dahut, MD, chief scientific officer at the ACS, said the data suggests screening conversations are happening too late for many men, particularly those at high risk.
When caught at a localized stage, the five-year survival rate for prostate cancer is nearly 100%. That rate drops significantly once the cancer has spread.
Black men face a disproportionate burden. Their incidence rate is approximately 67% higher than that of white men, and their mortality rate is more than twice as high. Experts say these disparities reflect both biological differences and unequal access to screening and care.
The ACS recommends that men at average risk discuss screening with their doctor at age 50. Men at high risk should have that conversation at 45, and those with multiple affected family members at 40.
The rise in cases follows a period of decline between 2007 and 2014, when changes in screening recommendations led fewer men to be tested. Oncologists say the current trend underscores the need for earlier, more consistent screening conversations.
